FMC Corporation 10-Q Summary: Period Ended June 30, 2026
Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 2026. FMC Corporation is a global agricultural sciences company operating in a single segment, developing crop protection chemicals (insecticides, herbicides, fungicides) and plant health products. The reporting period is characterized by significant strategic restructuring ("Project Foundation"), the divestiture of the India commercial business, and major capital market activities aimed at strengthening the balance sheet.
Key Financial Metrics
| Metric (Six Months Ended June 30, 2026) | Value ($ Millions) | Prior Year (Six Months Ended June 30, 2025) |
|---|---|---|
| Revenue | $1,625.7 | $1,841.9 |
| Gross Margin | $588.7 (36.2%) | $723.0 (39.3%) |
| Net Loss Attributable to FMC Stockholders | $(467.9) | $51.2 (Net Income) |
| Adjusted EBITDA (Non-GAAP) | $224.7 | $326.2 |
| Cash Flow from Operating Activities (Continuing Ops) | $(237.9) | $(479.1) |
| Total Debt | $4,280.6 | $4,074.9 |
| Cash and Cash Equivalents | $476.6 | $584.5 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 12% year-over-year (17% for the quarter) driven by a 7% price decline and 5% volume decrease. Key drivers included lower diamide partner orders, reduced demand for legacy products, and the exclusion of India revenue in the current period.
- Restructuring Charges: "Restructuring and other charges" surged to $299.3 million (vs. $54.5 million prior year). This includes $234.0 million in restructuring charges, primarily non-cash asset write-offs ($198.9 million) and accelerated depreciation under "Project Foundation," including a $70.6 million write-off of Latin American receivables due to commercial strategy changes.
- India Divestiture: The India commercial business is classified as "held for sale." An impairment charge of $43.6 million was recorded to adjust the carrying value to fair value less costs to sell. The business is expected to be sold for $252 million.
- Debt Restructuring: In June 2026, FMC issued $1.2 billion in 8.0% Senior Secured Notes due 2031. Proceeds were used to redeem $500 million of senior notes due in 2026 and repay borrowings under the Revolving Credit Facility. Interest expense increased 23% year-over-year due to higher debt balances and rates.
- Tax Provision: The effective tax rate for continuing operations was negative 32.2% (vs. 43.8% prior year), largely due to a $123 million increase in valuation allowance on historical deferred tax assets in Switzerland.
Guidance, Outlook, and Strategic Initiatives
- Project Foundation: Management expects total pre-tax restructuring charges of $700 million to $775 million over the life of the program (substantially complete by end of 2027). The program targets $200 million in annual run-rate savings by 2027.
- Strategic Investment: On June 30, 2026, FMC announced a strategic minority equity investment of approximately $400 million from the Tessenderlo Group at $13.30 per share. Proceeds will be used for debt reduction.
- Licensing Agreement: FMC entered a co-exclusive supply and license agreement with Corteva for rimisoxafen, receiving a $200 million initial prepurchase payment recognized as deferred revenue.
- Real Estate Sale: A framework agreement was signed to sell the Stine Research Center property in Newark, Delaware, for approximately $114 million, with proceeds intended for debt reduction.
- Dividends: The quarterly dividend was reduced to $0.08 per share in October 2025 to prioritize debt reduction. No share repurchases were made under the public program during the period due to credit agreement restrictions.
- 2026 Outlook: Management expects operating cash flow and free cash flow to improve in 2026 compared to 2025, driven by lower cash taxes and improved working capital, partially offset by lower Adjusted EBITDA and higher restructuring spending.
Investor Verification Checklist
- Restructuring Execution: Verify the progress of "Project Foundation" asset exits and the realization of the targeted $200 million annual run-rate savings.
- Transaction Closings: Monitor the regulatory approval and closing of the India business sale ($252 million), the Tessenderlo Group investment ($400 million), and the Newark property sale ($114 million).
- Debt Covenants: Confirm continued compliance with the amended credit agreement covenants, specifically the leverage and interest coverage ratios, given the recent debt refinancing.
- Valuation Allowance: Assess the sustainability of the $123 million valuation allowance recorded in Switzerland and its impact on future effective tax rates.
- Working Capital: Review the timing of receivable collections in Latin America and the impact of the commercial strategy shift on future cash flows.